EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions

Radica Z Alicic, Joshua J Neumiller

Cardiology Clinics · 2025

DOI: 10.1016/j.ccl.2024.12.003 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cardiology Clinics, 2025. Verfasst von Radica Z Alicic und 1 weiteren Autor:innen. Beteiligte Einrichtung: Providence Medical Research Center, Providence Inland Northwest Health, Spokane, WA, USA; Department of Medicine, University of Washington, Seattle, …. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Cardiovascular Diseases, Glucagon-Like Peptide 1, Gastric Inhibitory Polypeptide. Die Arbeit nennt 114 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Use of glucagon-like peptide-1 (GLP-1) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonists, initially developed as glucose-lowering therapies for the management of type 2 diabetes, continues to expand in parallel with our understanding of their beneficial effects on cardiovascular-kidney-metabolic conditions. Large clinical outcome trials have established GLP-1 receptor agonists as guideline-directed therapies to improve glycemia, achieve, and maintain weight management goals, and mitigate cardiovascular and kidney risk, with early evidence suggesting similar benefits with the dual GIP/GLP-1 receptor agonist tirzepatide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsCardiovascular DiseasesGlucagon-Like Peptide 1Gastric Inhibitory PolypeptideDiabetes Mellitus, Type 2Hypoglycemic AgentsHumansGlucagon-Like Peptide-1 Receptor

Stichwörter der Autor:innen

Cardiovascular outcome trialsDulaglutideExenatideIncretin hormonesLiraglutidePathomechanismsSemaglutideTirzepatide

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1Gastric Inhibitory PolypeptideHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • Providence Medical Research Center, Providence Inland Northwest Health, Spokane, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA. Electronic address: Radica.Alicic@providence.org.
  • Providence Medical Research Center, Providence Inland Northwest Health, Spokane, WA, USA; Department of Pharmacotherapy, College of Pharmacy and Pharmaceutical Sciences, Washington State University, 412 E. Spokane Falls…

Zitieren

APA

Alicic, R. Z., & Neumiller, J. J. (2025). Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions. Cardiology Clinics. https://doi.org/10.1016/j.ccl.2024.12.003

Vancouver

Alicic RZ, Neumiller JJ. Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions. Cardiology Clinics. 2025. doi:10.1016/j.ccl.2024.12.003

BibTeX
@article{Alicic2025,
  author = {Alicic, Radica Z and Neumiller, Joshua J},
  title = {Role of Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in Management of Cardiovascular-Kidney-Metabolic (CKM) Conditions},
  journal = {Cardiology Clinics},
  year = {2025},
  doi = {10.1016/j.ccl.2024.12.003}
}
Kostenlos starten →